[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350706-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350706-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","large-scale-simulation-of-coverage-and-error-rate-tradeoffs-for-cancer-detection-in-cell-free-dna-whole-genome-sequencing","Large-scale simulation of coverage and error rate tradeoffs for cancer detection in cell-free DNA whole-genome sequencing","","Large-scale simulation study for cfDNA whole-genome sequencing (WGS) quantifies how sequencing parameters shape tumor-derived ctDNA detection at low tumor fractions. Sequencing errors can create false positives indistinguishable from true single-nucleotide variants, making sensitivity highly dependent on coverage and base-calling quality. A framework simulates in silico cfDNA data across 10 cancer types, linking mutational load to detectable tumor fraction thresholds and guiding sequencing strategy optimization. Code is publicly available.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/large-scale-simulation-of-coverage-and-error-rate-tradeoffs-for-cancer-detection-in-cell-free-dna-whole-genome-sequencing/350706/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/large-scale-simulation-of-coverage-and-error-rate-tradeoffs-for-cancer-detection-in-cell-free-dna-whole-genome-sequencing/350706.png","ImageObject",300,407,{"name":42,"@type":43},"RuangKosong","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"为什么在 cfDNA WGS 中 ctDNA 检测会面临挑战？","Question",{"text":63,"@type":64},"因为测序平台会引入错误，这些错误产生的假阳性与真实单核苷酸变异在观测上难以区分，尤其当肿瘤分数（TF）很低时更明显。","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"研究如何模拟用于肿瘤检测的 cfDNA 数据？",{"text":68,"@type":64},"作者构建了一个仿真框架，根据肿瘤 WGS 配置文件生成体外数据，并在 10 种癌症类型上进行大规模并行模拟，共模拟 4.8 亿（480 million）cfDNA 样本。",{"name":70,"@type":61,"acceptedAnswer":71},"覆盖度与测序质量如何影响可检测的最低肿瘤分数？",{"text":72,"@type":64},"不同癌种在相同测序条件下最低可检测 TF 存在显著差异，受突变负荷影响。对高突变负荷癌种，3×覆盖度配合低错误技术可稳定检测低于 0.1% 的 TF；对低突变负荷癌种需要至少更高覆盖度（约六倍）以达到类似阈值，而将质量分数从 Q30 提升到 Q55 并在 30× 覆盖度下可将检测到的 TF 降至约 1×10−5。","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350706,1790189613,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Bioinformatics, 2026, 42, btag460  \n[https://doi.org/10.1093/bioinformatics/btag460](https://doi.org/10.1093/bioinformatics/btag460)  \n25th European Conference on Computational Biology supplement  \n| Large-scale simulation of coverage and error rate tradeoffs for cancer detection in cell-free DNA whole-genome sequencing\u003Cbr>Li-Ting Chen1,2,3, Jeroen de Ridder1,2,3,*, Myrthe Jager1,2,3,* |  |\n| --- | --- |\n| 1Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht 3584 CX, The Netherlands 2 Princess Mxima Center for Pediatric Oncology, Utrecht 3584 CS, The Netherlands\u003Cbr>3Oncode Institute, Utrecht 3521 AL, The Netherlands\u003Cbr>*Corresponding authors. Jeroen de Ridder, Princess Mxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. E-mail: [j.deridder-9@prinsesmaximacentrum.nl](j.deridder-9@prinsesmaximacentrum.nl); Myrthe Jager, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The [Netherlands. E-mail: m.jager-9@prinsesmaximacentrum.nl](Netherlands. E-mail: m.jager-9@prinsesmaximacentrum.nl).\u003Cbr>Abstract\u003Cbr>Motivation: Cell-free DNA (cfDNA) whole-genome sequencing (WGS) is a promising approach for detecting cancer recurrence. It enables cancer detection by identifying all tumor-derived cfDNA (ctDNA) molecules carrying somatic single nucleotide variants (sSNVs). While ideally, a sequencing platform should be highly accurate for reliable ctDNA detection, in reality, all sequencing platforms introduce sequencing errors that generate false positives indistinguishable from true SNVs. Understanding how sequencing parameters influence ctDNA detection sensitivity at low tumor fractions (TFs) incfDNA samples is essential for guiding sequencing strategies in clinical contexts. To model cfDNA sequencing for tumor detection, which contains asymmetric noise and multiple interacting parameters, analytical modeling is intractable, motivating large-scale parallelized simulation.\u003Cbr>Results: We developed a simulation framework to generate in silico cfDNA data across 10 cancer types. In total, 480 million cfDNA samples were simulated from tumor WGS profiles. Overall, the lowest detectable TF differs substantially between cancer types under identical sequencing conditions due to variations in mutational load. For cancers with high mutational load, 3× coverage with low-error techniques reliably detects TFs below 0.1%. In contrast, cancers with low mutational load require at least six-fold higher coverage to achieve comparable detection thresholds. Increasing sequencing quality scores from Q30 to Q55 at 30× coverage further enhances sensitivity, enabling detection of TFs as low as 1 × 10−5 . This study provides a comprehensive framework for optimizing sequencing parameters, offering valuable guidance for tailoring future technology development for specific cancer types and clinical applications.\u003Cbr>Availability and implementation: The code is publicly available at [https://github.com/UMCUGenetics/cfdetect/tree/main](https://github.com/UMCUGenetics/cfdetect/tree/main). |  |\n| 1 Introduction\u003Cbr>Early identification of cancer recurrence and minimal residual disease (MRD) substantially improves therapeutic efficacy and overall survival across nearly all cancer types (Crosby et al. 2022) . Liquid biopsy-based approaches, such as the analysis of tumor-derived cell-free DNA (ctDNA) in blood, offer a minimally invasive means to monitor cancer dynamics. ctDNA fragments recapitulate the genomic profile (i.e. mutations) of the tumor cells and thus serve as highly specific biomarkers (CisnerosVillanueva et al. 2022, Pascual et al. 2022) . Nevertheless, ctDNA detection remains technically challenging due to the typically low ctDNA fractions (tumor fraction; TF) in MRD and early recurrence (Azad et al. 2020, Bredno et al. 2022) . Digital-droplet PCR | (ddPCR) assays targeting individual mutations are routinely used in ","cbCaib2XHw5lox6r","https://ap.wps.com/l/cbCaib2XHw5lox6r","pdf",3035557,"English","# Abstract\n## Motivation\n## Results\n## Availability and implementation\n# Introduction\n## Liquid biopsy and ctDNA biomarkers\n## Technical challenges and sequencing tradeoffs\n# Approach overview","[{\"question\":\"为什么在 cfDNA WGS 中 ctDNA 检测会面临挑战？\",\"answer\":\"因为测序平台会引入错误，这些错误产生的假阳性与真实单核苷酸变异在观测上难以区分，尤其当肿瘤分数（TF）很低时更明显。\"},{\"question\":\"研究如何模拟用于肿瘤检测的 cfDNA 数据？\",\"answer\":\"作者构建了一个仿真框架，根据肿瘤 WGS 配置文件生成体外数据，并在 10 种癌症类型上进行大规模并行模拟，共模拟 4.8 亿（480 million）cfDNA 样本。\"},{\"question\":\"覆盖度与测序质量如何影响可检测的最低肿瘤分数？\",\"answer\":\"不同癌种在相同测序条件下最低可检测 TF 存在显著差异，受突变负荷影响。对高突变负荷癌种，3×覆盖度配合低错误技术可稳定检测低于 0.1% 的 TF；对低突变负荷癌种需要至少更高覆盖度（约六倍）以达到类似阈值，而将质量分数从 Q30 提升到 Q55 并在 30× 覆盖度下可将检测到的 TF 降至约 1×10−5。\"}]","Large-scale simulation of coverage and error rate tradeoffs for cancer detection in cell-free DNA whole-genome sequencing | PDF",1790090675,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc66a3e8b4d228e7e01aefeaa524fa20.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2f2a205e42f51ee8a27841037b15d2f.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f3bf713dc03b5425954257025577a31.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63e99a9edd8c0cf4ab926923e55b2831.webp",980,1287]